Importantly, because nontumor cells have not abrogated reserve MCM/CMG function due to anonco gene such as Myc, they would be predicted to display resistance to CMGi relative to the tumor cells, thus defining a therapeutic window for CMGi use. This evidence concerns the gene MYC and neoplasm.